BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

CNS disorders company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced Mark Schneyer as its first CBO. He was VP, business development at the Upjohn unit of Pfizer Inc. (NYSE:PFE). Hansa Biopharma AB (SSE:HNSA) said Achim Kaufhold will...
BioCentury | May 29, 2020
Product Development

Minerva’s schizophrenia miss casts doubt on approach to treating negative symptoms

Minerva’s Phase III miss in schizophrenia sent its shares down 72% on Friday, putting into doubt the future of the leading therapeutic candidate in development to treat the negative symptoms of schizophrenia -- an indication...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BC Extra | Dec 5, 2019
Clinical News

Dementia-related psychosis data could make Acadia’s pimavanserin a blockbuster

Pivotal data reported late Wednesday support Acadia’s bid for a label expansion that would bring pimavanserin to the broader population of dementia-related psychosis and help allay safety concerns associated with a black box on the...
BC Innovations | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

Minerva Neurosciences is on the precipice of two clinical readouts that could determine whether its founding bet on a pair of neuropsychiatry compounds from Mitsubishi Tanabe has panned out. Neither molecule represents a shift from...
BC Extra | Nov 5, 2019
Company News

Management tracks: Santhera, Acadia, Aeglea, Entrada, Kleo, Laboratory for Advanced Medicine, Imago, Glympse and Cognition

Santhera Pharmaceuticals Holding AG ( SIX:SANN) said Dario Eklund will succeed Thomas Meier as CEO, effective Dec. 1. Meier will remain on the rare neuromuscular and pulmonary disease company's board and chair its scientific committee. Eklund...
BC Extra | Sep 18, 2019
Financial News

Sept. 18 Financial Quick Takes: IGM gains in first trading day; plus a follow-on roundup, BenevolentAI, UCSF’s InVent Fund and Versantis

First-day pop for IGM on NASDAQ  Oncology antibody company IGM Biosciences Inc. (NASDAQ:IGMS) gained $8.30 (52%) to $24.30 in its first day of trading after raising $175 million in its IPO. IGM sold 10.9 million...
BC Extra | Sep 9, 2019
Clinical News

Dementia-related psychosis readout could lead to label expansion for Acadia's Nuplazid

A new Phase III readout could speed Acadia's timeline to a potential regulatory submission of pimavanserin to treat dementia-related psychosis, an indication that afflicts a much larger population than the one for which the molecule...
BC Extra | Aug 2, 2019
Company News

Aug. 1 Company Quick Takes: Nektar gains on breakthrough for NKTR-214; plus Adaptive's MRD test, Acadia, Vanda and more

Nektar gains after FDA breakthrough therapy designation  Nektar Therapeutics Inc. (NASDAQ:NKTR) was up $2.73 (10%) to $31.19 after FDA granted breakthrough designation for bempegaldesleukin (NKTR-214) in combination with Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY)...
BC Extra | Jul 23, 2019
Clinical News

Acadia looks to next schizophrenia readout after Phase III miss

Acadia shed $3.96 (15%) to $22.01 in after hours trading Monday when it reported after market close that Nuplazid pimavanserin as an adjunct schizophrenia therapy missed the primary endpoint and key secondary endpoint in the...
Items per page:
1 - 10 of 257
BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

CNS disorders company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced Mark Schneyer as its first CBO. He was VP, business development at the Upjohn unit of Pfizer Inc. (NYSE:PFE). Hansa Biopharma AB (SSE:HNSA) said Achim Kaufhold will...
BioCentury | May 29, 2020
Product Development

Minerva’s schizophrenia miss casts doubt on approach to treating negative symptoms

Minerva’s Phase III miss in schizophrenia sent its shares down 72% on Friday, putting into doubt the future of the leading therapeutic candidate in development to treat the negative symptoms of schizophrenia -- an indication...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BC Extra | Dec 5, 2019
Clinical News

Dementia-related psychosis data could make Acadia’s pimavanserin a blockbuster

Pivotal data reported late Wednesday support Acadia’s bid for a label expansion that would bring pimavanserin to the broader population of dementia-related psychosis and help allay safety concerns associated with a black box on the...
BC Innovations | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

Minerva Neurosciences is on the precipice of two clinical readouts that could determine whether its founding bet on a pair of neuropsychiatry compounds from Mitsubishi Tanabe has panned out. Neither molecule represents a shift from...
BC Extra | Nov 5, 2019
Company News

Management tracks: Santhera, Acadia, Aeglea, Entrada, Kleo, Laboratory for Advanced Medicine, Imago, Glympse and Cognition

Santhera Pharmaceuticals Holding AG ( SIX:SANN) said Dario Eklund will succeed Thomas Meier as CEO, effective Dec. 1. Meier will remain on the rare neuromuscular and pulmonary disease company's board and chair its scientific committee. Eklund...
BC Extra | Sep 18, 2019
Financial News

Sept. 18 Financial Quick Takes: IGM gains in first trading day; plus a follow-on roundup, BenevolentAI, UCSF’s InVent Fund and Versantis

First-day pop for IGM on NASDAQ  Oncology antibody company IGM Biosciences Inc. (NASDAQ:IGMS) gained $8.30 (52%) to $24.30 in its first day of trading after raising $175 million in its IPO. IGM sold 10.9 million...
BC Extra | Sep 9, 2019
Clinical News

Dementia-related psychosis readout could lead to label expansion for Acadia's Nuplazid

A new Phase III readout could speed Acadia's timeline to a potential regulatory submission of pimavanserin to treat dementia-related psychosis, an indication that afflicts a much larger population than the one for which the molecule...
BC Extra | Aug 2, 2019
Company News

Aug. 1 Company Quick Takes: Nektar gains on breakthrough for NKTR-214; plus Adaptive's MRD test, Acadia, Vanda and more

Nektar gains after FDA breakthrough therapy designation  Nektar Therapeutics Inc. (NASDAQ:NKTR) was up $2.73 (10%) to $31.19 after FDA granted breakthrough designation for bempegaldesleukin (NKTR-214) in combination with Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY)...
BC Extra | Jul 23, 2019
Clinical News

Acadia looks to next schizophrenia readout after Phase III miss

Acadia shed $3.96 (15%) to $22.01 in after hours trading Monday when it reported after market close that Nuplazid pimavanserin as an adjunct schizophrenia therapy missed the primary endpoint and key secondary endpoint in the...
Items per page:
1 - 10 of 257